Introduction: To evaluate the intermediate-term outcomes of thulium vapoenucleation of the prostate (ThuVEP) and thulium vaporesection of the prostate (ThuVaRP) in patients with benign prostate obstruction (BPO). Materials and Methods: A bicentric retrospective matched-paired comparison of patients treated by ThuVEP (n = 80) or ThuVaRP (n = 80) was performed. The patients were preoperatively assessed with International Prostate Symptom Score (IPSS), quality of life (QoL), post-void residual urine (PVR), maximum urinary flow rate (Qmax), prostatespecific antigen (PSA) and re-evaluated at 12- and 24-month follow-up. Results: Median prostate volume was 65 mL and not different between the groups. The immediate re-operation rate was significantly different between ThuVEP and ThuVaRP (5 vs. 0%, p ≤ 0.0434). IPSS, QoL, Qmax and PVR had improved significantly compared to preoperative assessment in both groups at 12- and 24-month follow-up (p ≤ 0.001). Median Qmax (18.2 vs. 21.0 mL/s) and PVR (29.4 vs. 0 mL) were significantly different between ThuVEP and ThuVaRP at 24-month follow-up (p ≤ 0.001), while IPSS and QoL showed no differences between the groups. However, the PSA reduction was significantly higher after ThuVEP compared to ThuVaRP (78.93 vs. 23.39%, p ≤ 0.006) at 24-month follow-up. Conclusions: ThuVEP and ThuVaRP are safe and efficacious procedures for patients with BPO. Although the peri-operative re-intervention rates were lower after ThuVaRP, the low PSA reduction rate after ThuVaRP at 24-month follow-up favours the ThuVEP procedure.

Keywords:
Benign prostatic obstruction, Vapoenucleation, Thulium:YAG, Revolix, Thulium vapoenucleation of the prostate, Thulium vaporesection of the prostate, Vaporesection
1.
Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O’Leary MP, Puppo P, Robertson C, Giuliano F: Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637–649.
2.
Gravas S, Bach T, Bachmann A, Drake M, Gacci M, Gratzke C, Madersbacher S, Mamoulakis C, Tikkinen KAO: Treatment of Non-Neurogenic Male LUTS. EAU Guidelines 2016. https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/#5 (August 8, 2016).
3.
Cornu JN, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, McVary K, Novara G, Woo H, Madersbacher S: A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol 2015; 67: 1066–1096.
4.
Tang K, Xu Z, Xia D, Ma X, Guo X, Guan W, Hu Z, Zhang X, Ye Z, Xu H: Early ou-tcomes of thulium laser versus transurethral resection of the prostate for managing benign prostatic hyperplasia: a syste-matic review and meta-analysis of comparative studies. J Endourol 2014; 28: 65–72.
5.
Netsch C, Bach T, Herrmann TR, Gross AJ: Update on the current evidence for Tm:YAG vapoenucleation of the prostate 2014. World J Urol 2015; 33: 517–524.
6.
Zhu Y, Zhuo J, Xu D, Xia S, Herrmann TR: Thulium laser versus standard transurethral resection of the prostate for benign prostatic obstruction: a systematic review and meta-analysis. World J Urol 2015; 33: 509–515.
7.
Yang Z, Wang X, Liu T: Thulium laser enucleation versus plasmakinetic resection of the prostate: a randomized prospective trial with 18-month follow-up. Urology 2013; 81: 396–400.
8.
Netsch C, Engbert A, Bach T, Gross AJ: Long-term outcome following Thulium VapoEnucleation of the prostate. World J Urol 2014; 32: 1551–1558.
9.
Xia SJ, Zhuo J, Sun XW, Han BM, Shao Y, Zhang YN: Thulium laser versus standard transurethral resection of the prostate: a randomized prospective trial. Eur Urol 2008; 53: 382–389.
10.
Fu WJ, Hong BF, Yang Y, Zhang X, Gao JP, Zhang L, Wang XX: Vaporesection for managing benign prostatic hyperplasia using a 2-µm continuous-wave laser: a prospective trial with 1-year follow-up. BJU Int 2008; 103: 352–356.
11.
Cui D, Sun F, Zhuo J, Sun X, Han B, Zhao F, Jing Y, Lu J, Xia S: A randomized trial comparing thulium laser resection to standard transurethral resection of the prostate for symptomatic benign prostatic hyperplasia: four-year follow-up results. World J Urol 2014; 32: 683–689.
12.
Sun F, Han B, Cui D, Zhao F, Sun X, Zhuo J, Jing Y, Liu H, Xia S, Yang Y, Luo G, Guo F: Long-term results of thulium laser resection of the prostate: a prospective study at multiple centers. World J Urol 2015; 33: 503–508.
13.
Si J, Gu B, Chen Z, Fu Q: The RevoLix(TM) 2-μm Continuous Wave Laser Vaporesection for the Treatment of Benign Prostatic Hyperplasia: Five-Year Follow-Up. Photomed Laser Surg 2016; 34: 297–299.
14.
Yu H, Zhang Z, Zhu Y, Chen J, Jiang X, Meng H, Shi B: Long-term outcome following thulium vaporesection of the prostate. Lasers Surg Med 2016; 48: 505–510.
15.
Yang Z, Liu T, Wang X: Comparison of thulium laser enucleation and plasmakinetic resection of the prostate in a randomized prospective trial with 5-year follow-up. Lasers Med Sci 2016; 31: 1797–1802.
16.
Netsch C, Magno C, Buttice S, Macchione L, Mucciardi G, Herrmann TR, Gross AJ: Thulium vaporesection of the prostate and Thulium vapoenucleation of the prostate in patients on oral anticoagulants: a retrospective three-centre matched-paired comparison. Urol Int 2015; 96: 421–426.
17.
Bach T, Netsch C, Haecker A, Michel MS, Herrmann TR, Gross AJ: Thulium:YAG laser enucleation (VapoEnucleation) of the prostate: safety and durability during intermediate-term follow-up. World J Urol 2010; 28: 39–43.
18.
Bach T, Netsch C, Pohlmann L, Herrmann TR, Gross AJ: Thulium:YAG vapoenucleation in large volume prostates. J Urol 2011; 186: 2323–2327.
19.
Bach T, Herrmann TR, Ganzer R, Burchardt M, Gross AJ: RevoLix vaporesection of the prostate: initial results of 54 patients with a 1-year follow-up. World J Urol 2007; 25: 257–262.
20.
Szlauer R, Götschl R, Razmaria A, Paras L, Schmeller NT: Endoscopic vaporesection of the prostate using the continuous-wave 2-microm thulium laser: outcome and demonstration of the surgical technique. Eur Urol 2009; 55: 368–375.
21.
Macchione L, Mucciardi G, Gali A, Di Benedetto A, Butticè S, Magno C: Efficacy and safety of prostate vaporesection using a 120-W 2-μm continuous-wave Tm:YAG laser (RevoLix 2) in patients on continuous oral anticoagulant or antiplatelet therapy. Int Urol Nephrol 2013; 45: 1545–1551.
22.
Peng B, Wang GC, Zheng JH, Xia SQ, Geng J, Che JP, Yan Y, Huang JH, Xu YF, Yang B: A comparative study of thulium laser resection of the prostate and bipolar transurethral plasmakinetic prostatectomy for treating benign prostatic hyperplasia. BJU Int 2013; 111: 633–637.
23.
Kim JW, Kim YJ, Lee YH, Kwon JB, Cho SR, Kim JS: An analytical comparison of short-term effectiveness and safety between Thulium:YAG laser vaporesection of the prostate and bipolar transurethral resection of the prostate in patients with benign prostatic hyperplasia. Korean J Urol 2014; 55: 41–46.
24.
Chung JS, Kang PM, Seo WI, Oh CK, Kim SC, Park SH, Choi JH, Yoon JH, Kang DI, Chung JI: Thulium laser (RevoLix) vaporesection versus vapoenucleation withmorcellator (Piranha) for the treatment of benign prostatic obstruction: a propensity-matched multicenter analysis. Int J Urol 2014; 21: 1156–1161.
25.
Wei H, Shao Y, Sun F, Sun X, Zhuo J, Zhao F, Han B, Jiang J, Chen H, Xia S:Thulium laser resection versus plasmakinetic resection of prostates larger than 80 ml. World J Urol 2014; 32: 1077–1085.
26.
Wei HB, Zhuo J, Sun XW, Pang K, Shao Y, Liang SJ, Cui D, Zhao FJ, Yu JJ, Xia SJ: Safety and efficiency of thulium laser prostate resection for the treatment of benign prostatic hyperplasia in large prostates. Lasers Med Sci 2014; 29: 957–963.
27.
Ahyai SA, Gilling P, Kaplan SA, Kuntz RM, Madersbacher S, Montorsi F, Speakman MJ, Stief CG: Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol 2010; 58: 384–397.
28.
Tinmouth WW, Habib E, Kim SC, Kuo RL, Paterson RF, Terry CL, Elhilali M, Lingeman JE: Change in serum prostate specific antigen concentration after holmium laser enucleation of the prostate: a marker for completeness of adenoma resection? J Endourol. 19: 550–554.
29.
Shah HN, Kausik V, Hegde S, Shah JN, Bansal MB (2006). Evaluation of fluid absorption during holmium laser enucleation of prostate by breath ethanol technique. J Urol. 175: 537–540.
30.
Gross AJ, Netsch C, Knipper S, Hölzel J, Bach T: Complications and early postoperative outcome in 1080 patients after thulium vapoenucleation of the prostate: results at a single institution. Eur Urol 2013; 63: 859–867.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.